Post-operative long-term adjuvant immunochemotherapy with mitomycin-C, PSK and FT-207 in gastric cancer patients.
Long-term adjuvant immunochemotherapy carried out on the gastrectomized patients with stomach cancer was reported. The protocol comprises the administration of large-dose of Mitomycin-C (20+10) mg just after gastrectomy and the long-term administration of PSK, FT-207 or (PSK+FT-207). Almost no side effects were observed. According to the studies on the immunological parameters, the increased reactions in PPD skin test and lymphocyte blastogenesis induced by PHA and PWM were observed remarkably in group (P+F) 3 or 6 months after gastrectomy. As for the survival rate, group (P+F) showed the most preferable results at one year in stage IV, at two years in stage III and at three years in all the stages, respectively after gastrectomy.
D000276:Adjuvants, Immunologic; D001487:Basidiomycota; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000031:analogs & derivatives*; D005743:Gastrectomy; D006801:Humans; D007167:Immunotherapy; D008937:Mitomycins / Q000008:administration & dosage*; D009367:Neoplasm Staging; D010835:Phytohemagglutinins / Q000494:pharmacology; D011184:Postoperative Period; D011509:Proteoglycans / Q000008:administration & dosage*; D012882:Skin Tests; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage*; D013997:Time Factors; D014374:Tuberculin Test
D000276:Adjuvants, Immunologic; D008937:Mitomycins; D010835:Phytohemagglutinins; D011509:Proteoglycans; D005641:Tegafur; D005472:Fluorouracil